News >

FDA Approval Sought for Tivozanib in Relapsed/Refractory Renal Cell Carcinoma

Jason M. Broderick @jasoncology
Published: Tuesday, Mar 31, 2020

Michael Bailey

Michael Bailey

A new drug application (NDA) has been submitted to the FDA for tivozanib (Fotivda) for the treatment of patients with relapsed/refractory renal cell carcinoma (RCC), according to Aveo Oncology, the company developing the VEGFR TKI.1
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication